VE-465
| Code | Size | Price |
|---|
| TAR-T29101-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
VE-465 is an inhibitor of Aurora kinase, which involves in multiple mitotic events.
CAS:
639089-73-9
Formula:
C22H28N8OS
Molecular Weight:
452.58
Purity:
0.98
SMILES:
CCC(=O)Nc1ccc(Sc2nc(Nc3cc(C)[nH]n3)cc(n2)N2CCN(C)CC2)cc1
References
1. Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24. Review. PubMed PMID: 26615129.
2. Cooper S, Giles FJ, Savona MR. Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma. 2009 Nov;50(11):1785-93. doi: 10.3109/10428190903267559. Review. PubMed PMID: 19883308.
3. Liang YQ, Chen BA, Chen YL. [Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):810-5. Review. Chinese. PubMed PMID: 19549414.
4. Chen XG, Zhang Y. [Recent advance in the study of novel anti-tumor targets and drugs--aurora kinase and Pin1]. Yao Xue Xue Bao. 2009 Mar;44(3):264-9. Review. Chinese. PubMed PMID: 19449522.